Navigation Links
Advair's Patient Share in Newly Diagnosed Asthma Patients is Declining
Date:12/1/2008

WALTHAM, Mass., Dec. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patient share for GlaxoSmithKline's Advair is declining in all lines of therapy for newly diagnosed asthma patients.

The new report entitled Treatment Algorithms in Asthma shows a reduction in Advair use in first-, second- and third-lines of therapy to 12.2 percent, 13.6 percent, and 14.6 percent, respectively when compared to the 2007 analysis that showed Advair was prescribed in 13.9 percent, 19.3 percent and 16.5 percent of first-, second- and third-line patients, respectively.

The decline in Advair's patient share is due to several factors: physicians' (particularly primary care physicians [PCPs]) increasing use of Merck's Singulair first-line, pushing Advair to later lines of therapy; specialists favoring newer once-daily inhaled corticosteroids (ICSs) with more favorable side-effect profiles in patients with less-severe disease prior to progressing to a long-acting beta2 agonist (LABA)/ICS combination; and physician movement towards using AstraZeneca's newly launched Symbicort as an alternative to Advair in later lines of therapy.

The report also finds that surveyed physicians will continue to use Singulair first-line regardless of March 2008 media reports linking the drug to behavior/mood changes and suicidality (suicidal thinking and behavior).

"The majority of pulmonologists, allergists and PCPs we surveyed told us that these media reports have had no effect on their treatment practice," added Dr. Westphal. "However, more surveyed allergists and PCPs told us that in the next two years they are likely to monitor their Singulair patients with increased vigilance, which likely reflects their treatment of a higher percentage of patients under the age of 18 compared with surveyed pulmonologists."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Natalia Morales                 Elizabeth Marshall
    Decision Resources              Decision Resources, Inc.
    781-296-2691                    781-296-2563
    nmorales@dresources.com         emarshall@dresources.com

'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Novel Techniques Offers New Freedom to Patients with Parkinson's Disease, Epilepsy, Dystonia, and Tremor
2. Prescription for patient safety
3. Transfusing Anemic Cancer Patients Boosts Clot Risk
4. Major North American breakthrough for dialysis patients
5. Blue Cross/Blue Shield Christmas Gift to Federal Employees: Surprise, Were Cutting Your Benefits!; Patients, Doctors and Health Care Providers Outraged
6. Singapore Caters to Middle East Medical Travelers with Arabic Version of Patients Beyond Borders-Singapore Edition
7. Pulmonary Hypertension Treated with Stem Cells : International Medical Team Announces Patient Results in Adult Stem Cell Clinical Study for Pulmonary Hypertension
8. Disclosure of medication can save a patients life
9. Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients
10. Doctors Receive Bonuses for Providing Optimal Care to Patients Through Bridges to Excellence
11. Transfusions increase clot risk in hospitalized cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , ... December 09, 2016 , ... ... at The Pierre Hotel in New York, NY, on December 3rd, to benefit ... and physicians attended the annual event, which raised over $1 million - the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa Wound ... Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the ... hospitals and facilities have earned this distinction. This is the second time the ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the promotions ... Eric Hoessel to vice president of sales. , Litsinger joined Mirixa in ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... vaccines market to grow at a CAGR of 6.83% during the ... the growth prospects of the global travel vaccines market for 2016-2020. ... from the sales of various vaccines administered to actively immunize meningococcal ...
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... , Dec. 8, 2016  The global biosurgery ... 8.8% during the forecast period of 2016 to 2021. ... by 2021 from USD 18.21 billion in 2016. The ... rising incidences of sports related injuries and spinal problems, ... rising need of effective blood loss management. ...
Breaking Medicine Technology: